CBER's Expedited IND pilot shifts first-in-human work ahead of the formal IND

What happened

On 4 November, FDA's Center for Biologics Evaluation and Research (CBER) set out how rolling submission will work in its Expedited IND Pilot. Most of the activity will happen before a formal IND exists. Sponsors will submit discipline-specific components during pre-IND development. A QRI will vet each component before the 30-day review begins.

The same day, FDA closed applications to the pilot after more than 100 submissions, with selections due by 18 December. The pilot sits under HHS Operation TrialBlazer. Its stated purpose is to test whether outside expert institutions and rolling review can speed first-in-human trials without lowering safety or oversight standards.

Why the structure matters

In the conventional route, a sponsor assembles the full IND package and submits it as one. The 30-day review then runs against that complete package. The pilot changes the sequence. Pieces of the package are submitted and vetted earlier, so the formal review starts with less left to discover.

The records do not say what the QRI checks, who staffs it, or whether it is an FDA or an external function. They do not say whether vetting results in feedback, a pass/fail gate, or something else. The records also do not spell out the acronym. Those details will decide how much time the design saves. A vetting step that surfaces deficiencies early moves the work upstream. One that adds a queue of its own could simply relocate the delay.

Cross-functional timing also changes. Discipline-specific components imply that, for example, CMC and nonclinical content may be submitted on different schedules instead of converging on one date. Teams used to a single assembly deadline would need to manage several. The records do not confirm which components are covered or in what order they are expected.

Regulatory context: early-phase review is being reworked elsewhere too

The US pilot is one of several recent moves to change how first-in-human work is prepared and assessed.

In the EU, ACT EU said on 3 November that its clinical trial application advice pilot becomes a permanent service from January 2027. The pre-submission advice procedure for sponsors using CTIS has run as a pilot since 2024. It will continue beyond 2026 with updated guidance and templates. The approach differs from CBER's. ACT EU offers advice before submission, while CBER's pilot builds vetting into the submission process itself. Both aim to resolve problems before a formal clock starts.

In the UK, the MHRA published guidance on 4 November on how it will assess non-clinical data generated outside the OECD Mutual Acceptance of Data (MAD) system. The guidance explains when trial applications relying on such safety data may be considered. It includes enhanced assessment in limited circumstances and a programme of test facility inspections. For sponsors, the lesson is similar. The provenance and quality of the nonclinical package is a front-end issue regulators are scrutinising closely.

Who is affected

The first group is the more than 100 applicants awaiting selection by 18 December. Those chosen will need to plan pre-IND development around staged component submissions. The records do not say how many will be selected, what eligibility criteria applied, or which product types are favoured beyond the biologics focus implied by CBER's role.

Sponsors not in the pilot are affected indirectly. If the pilot shows that early component vetting shortens the path to a first-in-human start, it may influence expectations for conventional INDs. The records do not indicate any such plan, and no evaluation metrics have been published in them.

Company disclosures show why early-phase timelines matter. Arvinas reported on 3 November that it had dosed its first patients with HPK1 degrader ARV-6723 in a Phase 1/2 solid tumour trial. It also plans EU and UK filings for ARV-102 in PSP. Xencor said it plans to meet FDA in the first half of 2027 about a possible accelerated approval route for XmAb819, after citing a 45.5% response rate in kidney cancer. Neither record links these companies to the pilot. They illustrate how much of a development programme's pace depends on early regulatory interactions.

What to watch

The 18 December selection date is the first marker. After that, the key questions are practical. How long does component vetting take? How is vetting feedback communicated? Does the 30-day review begin sooner, or run shorter, because of earlier work? None of this is answered in the records.

Also watch whether outside expert institutions are named and what role they play. CBER describes them as part of the test, but the records give no detail. Finally, watch how the pilot's safety and oversight commitments are measured, since faster first-in-human starts are only a success if standards hold.